We propose that a multi-targeted approach combining actions at 5-HT1A and 5-HT7 receptors could provide additional therapeutic benefits across a range of RDoC domains and hence be of clinical benefit trans-diagonistically beyond schizophrenia. This evidence concerns the gene HTR1A and schizophrenia.